ERBB2 and breast carcinoma: Therefore, this study examines and compares the clinical outcome of de novo metastatic HER2-low (IHC1+ or IHC2+/ISH-Negative) and HER2-zero (IHC 0) breast cancer using the NCDB, a national cancer outcome dataset in the United States.